Top Topics

To read this article for freeRegister nowOnce registered, you can:• Read free articles • Get our Editor's Digest and other newsletters ...

US stocks tumbled on Friday, weighed down by intensifying concerns about the US jobs market and rising energy prices triggered by the war in Iran.The S&P 500 fell 1.3 per cent, taking the loss for Wall Street’s benchmark index...

bk: michael, reminder to please fill our your disclosure when you have a second. it’s the red button at rightThe “fog of war” refers to confusion and uncertainty on the battlefield and the attendant possibility...

Who should control AI? Are the corporations that release the powerful technology the arbiters of its fate? Or should that power be vested in the hands of the government?Palmer Luckey, the founder of defense company Anduril—which aims to modernize...

Unlock the White House Watch newsletter for freeYour guide to what Trump’s second term means for Washington, business and the worldThe US Development Finance Corporation is creating a $20bn reinsurance facility to restart maritime cargo and oil commerce stalled...

Vinod Khosla has been thinking about artificial intelligence longer than most, and betting on it longer than almost anyone. The legendary venture capitalist who scored a 2,500x return with Juniper Networks and became the first institutional investor in OpenAI—wiring...

The Supreme Court’s decision to strike down the bulk of President Donald Trump’s tariffs has created a consolation prize for the administration hellbent on using tariff revenue to bolster the U.S. economy. While the loss of an estimated $300...

Michael W. Green, a Wall Street investor, created a buzz in late 2025 by arguing that the U.S. poverty line should be jacked up to US$140,000 for a family of four. Currently, a family of...

The fear that artificial intelligence (AI) will hollow out the workforce has dominated corporate boardrooms and business headlines for years, and gathered pace in early 2026. But one of banking’s most influential talent executives says the math actually points...

(Bloomberg) — Generic versions of Novo Nordisk A/S’s hit shots Ozempic and Wegovy could be sold for under $3 a month, a new study showed, underscoring their potential to unlock global access to powerful weight-loss drugs. Read More Source link...